UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

(Amendment No.)
Filed by the Registrant ⊠ Filed by a Party other than the Registrant □
Check the appropriate box: ☐ Preliminary Proxy Statement
\Box Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
☐ Definitive Proxy Statement
☑ Definitive Additional Materials
☐ Soliciting Material under §240.14a-12
DIAMEDICA
DiaMedica Therapeutics Inc.
(Name of Registrant as Specified In Its Charter)
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check all boxes that apply): ☑ No fee required
☐ Fee paid previously with preliminary materials
☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11



DIAMEDICA THERAPEUTICS INC.

2024 Annual General Meeting Vote by May 21, 2024 11:59 PM ET



DIAMEDICA THERADEUTICS INC 301 CARLSON PARKWAY 9JITE 210 MINNEAPOLIS, WN 55305

Dia Medica

V32126-P03776

You invested in DIAMEDICA THERAPEUTICS INC. and it's time to vote!

You have the right to vote on proposals being presented at the Annual General Meeting. This is an important notice regarding the availability of proxy material for the shareholder meeting to be held on May 22, 2024.

Get informed before you vote

View the Notice and Proxy Statement and 2023 Annual Report online OR you can receive a free paper or email copy of the material(s) by requesting prior to May 8, 2024. If you would like to request a copy of the material(s) for this and/or future shareholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.



For complete information and to vote, visit www.ProxyVote.com

Control #

Smartphone users

Point your camera here and vote without entering a control number



Vote in Person at the Meeting*

May 22, 2024 9:00 AM CDT

301 Carlson Parkway Suite 210 Minneapolis, Minnesota 55305, USA



THIS IS NOT A VOTABLE BALLOT

This is an overview of the proposals being presented at the upcoming shareholder meeting. Please follow the instructions on the reverse side to vote these important matters.

ing Items	Board Recommends
To elect seven persons to serve as directors until our next Annual General Meeting of Shareholders or until their respective successors are elected and qualified (Voting Proposal One).	1888800000
Nominees:	
Michael Giuffre, M.D.	For
Richard Kuntz, M.D., M.Sc.	O For
Tanya Lewis	⊘ For
James Parsons	For
Rick Pauls	For
Richard Pilnik	For
Charles Semba, M.D.	For
To consider a proposal to appoint Baker Tilly US, LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024 and to authorize the Board of Directors to fix our independent registered public accounting firm's remuneration (Voting Proposal Two).	⊘ For
To consider a proposal to approve an amendment to the DiaMedica Therapeutics Inc. Amended and Restated 2019 Omnibus Incentive Plan to increase the number of shares available under the plan by 3,000,000 shares (Voting Proposal Three).	⊘ For
To approve, on an advisory (non-binding) basis, our executive compensation (Voting Proposal Four).	For
To approve, on an advisory (non-binding) basis, the frequency of future advisory votes on executive compensation (Voting Proposal Five).	1 Year
TE: To transact such other business as may properly come before the meeting or any adjournment of the meeting.	
	To elect seven persons to serve as directors until our next Annual General Meeting of Shareholders or until their respective successors are elected and qualified (Voting Proposal One). Nominees: Michael Giuffre, M.D. Richard Kuntz, M.D., M.Sc. Tanya Lewis James Parsons Rick Pauls Richard Pilnik Charles Semba, M.D. To consider a proposal to appoint Baker Tilly US, LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2024 and to authorize the Board of Directors to fix our independent registered public accounting firm's remuneration (Voting Proposal Two). To consider a proposal to approve an amendment to the DiaMedica Therapeutics Inc. Amended and Restated 2019 Omnibus Incentive Plan to increase the number of shares available under the plan by 3,000,000 shares (Voting Proposal Three). To approve, on an advisory (non-binding) basis, our executive compensation (Voting Proposal Four). To approve, on an advisory (non-binding) basis, the frequency of future advisory votes on executive compensation

V32127-P03776

Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click "Delivery Settings".